根据世界卫生组织预测，全球每年约有10亿例季节性流感病例，包括300万至500万例重症病例。在此 背景下，抗流感药物市场空间广阔。据头豹研究院预测，2024—2028年中国抗流感用药市场规模将以 20.2%的年复合增长率持续增长，到2028年有望达到269亿元。 （资料参考：21世纪经济报道《抗流 感药需求激增：市场"厮杀"升级，谁能抢占C位？》,2025.11.3) 今年，多款国产抗流感创新药密集获批上市，引发市场高度关注，2025年甚至被称为"国产流感创新 药元年"。有业内人士表示，国产流感创新药密集取得进展，是我国医药创新能力持续提升的必然结 果。这背后蕴藏着什么投资机遇？ （资料参考：证券日报《国产创新药破局 为应对流感提供"中国方 案"》，2025.11.12） 国产流感创新药商业化提速 2025年3月至7月，我国有三款抗流感创新药（玛舒拉沙韦片、昂拉地韦片、玛硒洛沙韦片）获批上 市，另有两款药物（玛氘诺沙韦、玛帕西沙韦）完成临床试验，已经提出了上市申请，预计不久将加 入市场竞争。专业人士分析称，目前国产创新药上市以后，销量在稳步提升，反映出这些产品在疗 效、安全性方面获得了认可。 （资料参考：央广 ...

百亿市场待重构，替代空间广阔 今年，多款国产抗流感创新药密集获批上市，引发市场高度关注，2025年甚至被称为"国产流感创新药 元年"。有业内人士表示，国产流感创新药密集取得进展，是我国医药创新能力持续提升的必然结果。 这背后蕴藏着什么投资机遇？（资料参考：证券日报《国产创新药破局 为应对流感提供"中国方 案"》，2025.11.12） 国产流感创新药商业化提速 2025年3月至7月，我国有三款抗流感创新药（玛舒拉沙韦片、昂拉地韦片、玛硒洛沙韦片）获批上市， 另有两款药物（玛氘诺沙韦、玛帕西沙韦）完成临床试验，已经提出了上市申请，预计不久将加入市场 竞争。专业人士分析称，目前国产创新药上市以后，销量在稳步提升，反映出这些产品在疗效、安全性 方面获得了认可。（资料参考：央广网《全国整体进入流感流行季 多款国产流感创新药密集上市》， 2025.11.21；36氪《围剿"流感神药"奥司他韦，药厂卷起"一次治疗"新战场》，2025.11.14） 突破进口药局限，实现多重优化 国产新药与进口流感药玛巴洛沙韦作用机制相同，都是通过抑制流感病毒的CAP帽子结构依赖性内切 酶，从而阻断病毒复制。值得关注的是，这批国产新药并非简 ...

Core Insights - The article discusses the recent launch of three domestic influenza innovative drugs in China, highlighting their effectiveness and market potential as flu activity rises across the country [1][2]. Group 1: Product Overview - Three domestic influenza innovative drugs have been approved for market: 1. Marzula Shave Tablets (Yisuda) by Jiangxi Kairui Pharmaceutical Co., a subsidiary of Qingfeng Pharmaceutical Group [1]. 2. Angladiwei Tablets (Anruiwei) by Guangdong Zhongsheng Pharmaceutical Co., a subsidiary of Guangdong Zhongsheng Ruichuang Biotechnology Co. [1]. 3. Maxiluo Shave Tablets (Jike Shu) developed by Hubei Jichuan Pharmaceutical Co. in collaboration with Nanjing Zhengxiang Pharmaceutical Co. [1]. - These drugs have achieved breakthroughs in "one-time dosing" and effectiveness against flu viruses, particularly for adolescents [2]. Group 2: Efficacy and Clinical Trials - Jichuan Pharmaceutical's Jike Shu is a new generation targeted RNA polymerase PA inhibitor, requiring only one dose for treatment of uncomplicated influenza in healthy adults [2]. - Angladiwei is the world's first oral drug targeting the RNA polymerase PB2 for type A influenza, showing significant symptom relief and low resistance in clinical trials [2]. - Health元 Pharmaceutical's Marpashisave Capsules are positioned to outperform existing treatments for type B influenza and in pediatric patients, utilizing a novel mechanism to inhibit viral replication [2]. Group 3: Supply Chain and Market Readiness - Companies report sufficient supply and production capacity to meet the increasing demand during the winter-spring season [3]. - Angladiwei is available through public medical institutions, major pharmacy chains, and online platforms, ensuring a robust supply chain [3]. - Jike Shu has launched on the JD Health platform, with ongoing market promotion efforts [3]. Group 4: Market Strategy and Future Outlook - Experts suggest that pharmaceutical companies should aim to be included in the dynamic adjustments of the national medical insurance catalog and enhance hospital channel coverage [4]. - As domestic influenza innovative drugs establish a stable supply system and gain positive reputations, they are expected to gradually increase their market share [4].

Core Viewpoint - The flu season in China is expected to peak in late December and early January, with a significant rise in flu activity currently observed, particularly with the H3N2 subtype dominating [1][4]. Group 1: Market Demand and Supply - Orders for flu medications have more than doubled since November, with northern cities like Harbin and Shenyang seeing increases over 150% [2]. - The supply of both imported and domestic flu medications is currently adequate, with regular restocking occurring in pharmacies [4]. - Domestic pharmaceutical companies have reported a significant increase in the procurement of cold and fever medications, indicating heightened consumer demand [2][4]. Group 2: Innovation in Domestic Pharmaceuticals - Several domestic flu medications have been approved this year, leading to a belief that 2025 may be the "year of domestic flu innovation drugs" [4][5]. - Three new antiviral flu medications have been approved, with two more completing clinical trials and seeking market approval [4]. - The domestic pharmaceutical industry is experiencing a shift towards innovative drug development, with companies focusing on both efficacy and safety [5]. Group 3: Industry Dynamics and Challenges - The rise in flu medication production is attributed to the seasonal nature of flu outbreaks and the strategic importance of the biopharmaceutical industry [5]. - Companies face challenges in promoting new medications, requiring collaboration with local governments, hospitals, and pharmacies to ensure prescriptions are written for innovative drugs [6]. - The domestic pharmaceutical industry is evolving, with a focus on mastering core technologies and competing with international firms [6].

Core Insights - The article highlights the rise of domestic innovative flu medications in China, marking 2025 as a significant year for the industry, with a notable increase in flu activity reported in southern and northern provinces [1][2]. Group 1: Market Developments - A total of 347 flu-like outbreak cases were reported nationwide as of November 2, 2025, indicating a growing demand for flu medications [1]. - Several domestic innovative flu drugs have been approved this year, including "Yisuda" (Marshularsavir Tablets) and "Anruiwei" (Angladiwe Tablets), which were launched in March and May respectively [1][2]. - The innovative drug "Makexiluo Savir Tablets" was approved in July through a collaboration between Hubei Jichuan Pharmaceutical and Nanjing Zhengxiang Pharmaceutical [2]. Group 2: Industry Trends - Domestic pharmaceutical companies are actively enhancing awareness among healthcare professionals and the public regarding the characteristics of their products, indicating progress in commercialization [2]. - The market share of imported flu medications, particularly Oseltamivir, which previously dominated with over 80%, is expected to be challenged by the new domestic offerings [2][4]. Group 3: Policy Support - The development of domestic innovative drugs is supported by government policies, including measures from the National Healthcare Security Administration and the National Health Commission aimed at promoting high-quality development of innovative drugs [3]. - The policies focus on increasing support for R&D, facilitating access to basic medical insurance, and enhancing clinical application and payment capabilities for innovative drugs [3]. Group 4: Future Outlook - There is a strong intention among domestic innovative flu drug manufacturers to enter the medical insurance system, which could lead to price reductions if negotiations are successful [4]. - The rapid development of innovative flu medications is seen as a significant step for China's pharmaceutical industry, which is also expanding into other therapeutic areas such as oncology and infectious diseases [4].